Physicians’ Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors

Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin), although initially developed as glucose-lowering drugs, provide significant beneficial effects on cardiorenal outcomes, including heart failure, regardless of type 2 diabetes status...

Descripción completa

Detalles Bibliográficos
Autores principales: Jabbour, Serge A., Ibrahim, Nasrien E., Argyropoulos, Christos P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604628/
https://www.ncbi.nlm.nih.gov/pubmed/36294370
http://dx.doi.org/10.3390/jcm11206051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604628/
https://www.ncbi.nlm.nih.gov/pubmed/36294370
http://dx.doi.org/10.3390/jcm11206051

Ejemplares similares